Italia markets close in 3 hours 5 minutes

Novo Nordisk A/S (0TDD.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
109,70-0,64 (-0,58%)
Al 06:46PM BST. Mercato aperto.
Schermo intero
Chiusura precedente110,34
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno108,39 - 109,70
Intervallo di 52 settimane108,39 - 109,70
Media VolumeN/D
Beta (5 anni mensile)0,24
Rapporto PE (ttm)36,16
EPS (ttm)3,03
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Novo Nordisk A/S: Share repurchase programme

    Bagsværd, Denmark, 4 July 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiate

  • GlobeNewswire

    Novo Nordisk A/S: Sogroya® data show potential as once-weekly treatment in children living with growth hormone deficiency

    Investigational phase 3 data for Sogroya® (somapacitan) injection in children with growth hormone deficiency presented today at the ENDO 2022 Congress1 Atlanta, Georgia (US), 12 June 2022 – Today, Novo Nordisk announced results of once-weekly Sogroya® (somapacitan) injection in helping children achieve growth targets of annualised height velocity (AHV).1 These phase 3 results from the REAL 4 study, in prepubertal children with growth hormone deficiency (GHD), were presented today at the Endocrin

  • GlobeNewswire

    Novo Nordisk A/S:

    Novo Nordisk – major shareholder announcement Bagsværd, Denmark, 7 June 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 31 May 2022 holds B shares equal to below 5% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section